Shanghai Fosun Pharmaceutical (Group) Co Ltd 2021 AR2
The report highlights Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s steady business development in 2021, with revenue reaching RMB 38,858 million, a 28.83% year-on-year increase. Under its '4IN' strategy, the company accelerated R&D and innovation, with total R&D expenditure increasing by 24.28% to RMB 4,975 million. Key innovative products like Comirnaty (mRNA COVID-19 vaccine) and Yi Kai Da (the first approved domestic CAR-T cell therapy) achieved significant milestones. Additionally, the company advanced its global operations, with overseas revenue accounting for 35% of total revenue, and committed to its second five-year environmental strategic goals to reduce carbon emissions and energy consumption intensity.
Company: Shanghai Fosun Pharmaceutical (Group) Co Ltd
Sector: Manufacturing
Country: China
Year: 2021
Type: AR2
Pages: 327
Back to company
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Annual Report
The report highlights Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s steady business development in 2021, with revenue reaching RMB 38,858 million, a 28.83% year-on-year increase. Under its '4IN' strategy, the company accelerated R&D and innovation, with total R&D expenditure increasing by 24.28% to RMB 4,975 million. Key innovative products like Comirnaty (mRNA COVID-19 vaccine) and Yi Kai Da (the first approved domestic CAR-T cell therapy) achieved significant milestones. Additionally, the company advanced its global operations, with overseas revenue accounting for 35% of total revenue, and committed to its second five-year environmental strategic goals to reduce carbon emissions and energy consumption intensity.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees